Skip to main contentSkip to navigationSkip to search

ENEA 2025

CAM2029 octreotide subcutaneous depot maintains control of IGF-I and symptoms of acromegaly across a 4-week dosing interval and for intervals greater than 28 days: data from the ACROINNOVA 1 trial

Click the material you wish to view

ACROINNOVA 1 IGF-I stability poster

PDF

ACROINNOVA 1 IGF-I stability poster supplementary

PDF

See all posters presented at
ENEA 2025

Explore more

Disease areas

Camurus is committed to improving treatment outcomes and quality of life for people with severe and chronic diseases.

Congresses

Discover Camurus’ engagement at conducted and upcoming international medical conferences and events.